olaparib
Showing 26 - 50 of 385
Prostate Cancer Trial in Lexington (biological, drug, radiation)
Not yet recruiting
- Prostate Cancer
- Pembrolizumab
- +3 more
-
Lexington, KentuckyUniversity of Kentucky
Oct 3, 2022
Gastroenteropancreatico Tumors, Neuroendocrine Tumors, Neuroendocrine Tumors Trial run by the National Cancer Institute (NCI)
Recruiting
- Gastroenteropancreatico Tumors
- +2 more
- Lu-177-DOTATATE
- +4 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 19, 2023
ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer, a Germline or Somatic BRCA Mutation, or a
Recruiting
- ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer
- a Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status
- Durvalumab
- +2 more
-
Montpellier, France
- +1 more
Nov 16, 2022
EGFR-Mutated Non-Small-Cell Lung Carcinoma, Small Cell/Neuroendocrine Trial run by the National Cancer Institute (NCI)
Recruiting
- EGFR-Mutated Non-Small-Cell Lung Carcinoma
- Small Cell/Neuroendocrine
- Olaparib
- Durvalumab
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 20, 2023
Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma Trial in Seattle (Olaparib)
Recruiting
- Castration-Resistant Prostate Carcinoma
- Prostate Adenocarcinoma
- Olaparib
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Aug 23, 2022
Breast Cancer Trial in Spain (Olaparib)
Terminated
- Breast Cancer
- Olaparib
-
Barcelona, Spain
- +7 more
Jan 18, 2023
Chronic Lymphocytic Leukemia Trial in Salt Lake City (RP-3500 in combination with Olaparib)
Recruiting
- Chronic Lymphocytic Leukemia
- RP-3500 in combination with Olaparib
-
Salt Lake City, UtahHuntsman Cancer Institute at the University of Utah
Sep 23, 2022
Recurrent Metastatic Melanoma, Cutaneous Melanoma, Mucosal Melanoma Trial in Boston (Olaparib)
Not yet recruiting
- Recurrent Metastatic Melanoma
- +3 more
- Olaparib
-
Boston, Massachusetts
- +1 more
Jul 29, 2022
Locally Advanced Leiomyosarcoma, Metastatic Leiomyosarcoma, Stage III Uterine Corpus Leiomyosarcoma AJCC v8 Trial in New York
Recruiting
- Locally Advanced Leiomyosarcoma
- +5 more
- Olaparib
- +3 more
-
New York, New YorkColumbia University/Herbert Irving Cancer Center
Jan 4, 2023
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma Trial in Boston, Houston
Recruiting
- Recurrent Fallopian Tube Carcinoma
- +2 more
- Adavosertib
- +2 more
-
Boston, Massachusetts
- +1 more
Jan 12, 2023
First-line Olaparib Combined With Bevacizumab Maintenance
Not yet recruiting
- Ovarian Neoplasms
- olaparib plus bevacizumab maintenance therapy
- (no location specified)
Jun 29, 2022
Ovarian Cancer Trial in Birmingham (Carboplatin, olaparibp, embro)
Not yet recruiting
- Ovarian Cancer
- Carboplatin
- olaparibp, embro
-
Birmingham, AlabamaO'Neal Comprehensive Cancer Center at UAB
Jul 18, 2023
Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma Trial in Seattle (biological, drug, other)
Recruiting
- Biochemically Recurrent Prostate Carcinoma
- Prostate Adenocarcinoma
- Durvalumab
- +3 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jan 26, 2023
Laryngeal Cancer Stage II, Laryngeal Cancer Stage III, Carcinoma, Squamous Cell Trial in Amsterdam (radiotherapy, Olaparib)
Active, not recruiting
- Laryngeal Cancer Stage II
- +3 more
- radiotherapy
- Olaparib
-
Amsterdam, NetherlandsThe Netherlands Cancer Institute
Sep 27, 2022
Lung Cancer Trial in Korea, Republic of (Olaparib+Bevacizumab to SCLC patients)
Recruiting
- Lung Cancer
- Olaparib+Bevacizumab to SCLC patients
-
Seoul, Gangnam-gu, Korea, Republic of
- +3 more
Nov 9, 2022
Squamous Cell Carcinoma of Head and Neck Trial in Chapel Hill, Charleston (biological, drug, radiation)
Recruiting
- Squamous Cell Carcinoma of Head and Neck
- Pembrolizumab
- +3 more
-
Chapel Hill, North Carolina
- +1 more
Oct 25, 2022
Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Recurrent Malignant Solid Tumor Trial (procedure, biological,
Not yet recruiting
- Advanced Malignant Solid Neoplasm
- +2 more
- Biopsy
- +5 more
- (no location specified)
Apr 8, 2023
Head Neck Cancer Trial in London, Wales (Olaparib, Cisplatin, IMRT)
Active, not recruiting
- Head and Neck Cancer
- Olaparib
- +2 more
-
London, United Kingdom
- +2 more
Nov 1, 2022
Advanced Ovarian Cancer Trial in Spain (Olaparib, Pegylated Liposomal Doxorubicin)
Completed
- Advanced Ovarian Cancer
- Olaparib
- Pegylated Liposomal Doxorubicin
-
Sabadell, Barcelona, Spain
- +7 more
Jan 25, 2023
Renal Cell Carcinoma, Ovarian Carcinoma, Thyroid Carcinoma Trial in Groningen (Olaparib, Lenvatinib, Sunitinib)
Not yet recruiting
- Renal Cell Carcinoma
- +4 more
- Olaparib
- +4 more
-
Groningen, NetherlandsUniversity Medical Center Groningen
Jul 13, 2023
Cervical Cancer Trial in Hidaka (Pembrolizumab, Olaparib)
Active, not recruiting
- Cervical Cancer
- Pembrolizumab
- Olaparib
-
Hidaka, Saitama, JapanSaitama Medical Uiversity International Medical Center
Aug 8, 2022
Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma Trial in Seattle (Laboratory Biomarker Analysis, Olaparib,
Active, not recruiting
- Castration-Resistant Prostate Carcinoma
- Prostate Adenocarcinoma
- Laboratory Biomarker Analysis
- +5 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Oct 19, 2022
High Grade Serous Carcinoma, Triple Negative Breast Cancer, Ovarian Cancer Trial (Olaparib tablet, Navitoclax)
Recruiting
- High Grade Serous Carcinoma
- +2 more
- Olaparib tablet
- Navitoclax
-
Toronto, Ontario, Canada
- +2 more
Nov 28, 2022
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma
Not yet recruiting
- Anatomic Stage III Breast Cancer AJCC v8
- +3 more
- Alpelisib
- +7 more
- (no location specified)
Jul 28, 2023
Endometrial Serous Adenocarcinoma, Metastatic Malignant Solid Tumor, Unresectable Malignant Solid Tumor Trial in United States
Recruiting
- Endometrial Serous Adenocarcinoma
- +2 more
- Biopsy
- +3 more
-
Phoenix, Arizona
- +3 more
Feb 2, 2023